<code id='415589DC54'></code><style id='415589DC54'></style>
    • <acronym id='415589DC54'></acronym>
      <center id='415589DC54'><center id='415589DC54'><tfoot id='415589DC54'></tfoot></center><abbr id='415589DC54'><dir id='415589DC54'><tfoot id='415589DC54'></tfoot><noframes id='415589DC54'>

    • <optgroup id='415589DC54'><strike id='415589DC54'><sup id='415589DC54'></sup></strike><code id='415589DC54'></code></optgroup>
        1. <b id='415589DC54'><label id='415589DC54'><select id='415589DC54'><dt id='415589DC54'><span id='415589DC54'></span></dt></select></label></b><u id='415589DC54'></u>
          <i id='415589DC54'><strike id='415589DC54'><tt id='415589DC54'><pre id='415589DC54'></pre></tt></strike></i>

          explore

          explore

          author:knowledge    Page View:9948
          The headquarter of US biopharmaceutical company Vertex Pharmaceuticals with its logo sign— coverage from STAT
          JOSEPH PREZIOSO/AFP via Getty Images

          LONDON — The U.K.’s cost-effectiveness watchdog said Thursday it is not yet recommending Vertex’s CRISPR-based therapy for sickle cell disease, saying in draft guidance it has questions about the medicine’s lasting benefits for patients.

          U.K. regulators approved the therapy, known as Casgevy or exa-cel, last year, granting it the world’s first authorization for any CRISPR-based medicine. But observers have been watching to see how the U.K.’s National Institute for Health and Care Excellence, as well as similar agencies in European countries, would view the pricey, one-time therapy. NICE needs to recommend the therapy for it to be offered in the National Health Service.

          advertisement

          In the U.S., Casgevy has a list price of $2.2 million. It was developed by Vertex in partnership with CRISPR Therapeutics.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          United colonoscopy coverage change 'may cost lives,' doctors say
          United colonoscopy coverage change 'may cost lives,' doctors say

          AdobeWhengastroenterologistslearnedinMarchthatUnitedHealthcareplanstobarricademanycolonoscopiesbehin

          read more
          Pregnant women don't need prenatal multivitamins, study concludes
          Pregnant women don't need prenatal multivitamins, study concludes

          APStockPrenatalvitaminsareastapleofmodernpregnancy. ButareportoutMondayin thejournalDrugandTherapeut

          read more
          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more

          Bristol 'take

          MollyFerguson/STATSomeday-afterthoughtsonBristolMyersSquibbacquiringMiratiTherapeutics:Atake-underde